XYLYX BIO launches specialized contract R&D services that increase predictiveness in antifibrotic drug discovery
NEW YORK, Sept. 29, 2020 /PRNewswire/ — Xylyx Bio, a leader in advanced disease models for drug discovery, today announced the launch of specialized contract R&D services that support improved assessment of antifibrotic drug candidate efficacy. Despite ongoing advances, the current drug…
Comments Off on XYLYX BIO launches specialized contract R&D services that increase predictiveness in antifibrotic drug discovery